A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome,
Role: Investigator,
Furiex Pharmaceuticals,
(07/2012 - 07/2013)
Status: Completed
A multicenter, randomized, placebo-controlled, doubleblinded study of the efficacy and safety of lubiprostone in patients with opioid-induced bowel dysfuction,
Role: Investigator,
Sucampo Pharmaceuticals, Inc.,
(01/2009 - 01/2010)
Status: Completed
Internal
Prevalence of 30-day readmission rates for patients discharged from acute care hospital on parenteral nutrition,
Role: Investigator,
LLU Dept. of Medicine,
(09/2019)
Status: Approved